AbbVie cancer drug fails two late-stage studies

AbbVie cancer drug fails two late-stage studies

PanARMENIAN.Net - AbbVie Inc said on Wednesday, April 19 that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies, Reuters reports.

The trials evaluated the effect of veliparib, in combination with a chemotherapy regimen, on patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer.

In one trial, the combination treatment failed to improve the overall survival of NSCLC patients, who had smoked within the past 12 months and had more than 100 smoking events in their lifetime.

In another trial, which evaluated the treatment on patients with early-stage triple-negative breast cancer, the drug did not achieve the complete pathologic response.

Veliparib belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.

The only approved drugs in the class include AstraZeneca Plc's Lynparza, also known as olaparib, and Tesaro Inc's niraparib.

Other experimental PARP inhibitors include Clovis Oncology Inc's rucaparib and Pfizer Inc's talazoparib.

Photo. REUTERS/Brendan McDermid
 Top stories
The public learnt about the mass torture in 2019, when the details of the case gradually began to be revealed.
The Babakyar mountains includes territory from all the South Caucasian countries - Azerbaijan, Armenia and Georgia.
The House of Representatives overwhelmingly voted Tuesday, October 29 to officially recognize the Armenian Genocide.
French actor of Armenian descent Charles Gérard died September 19 at the age of 96, Figaro reports.
Partner news